Nanna’s recent hiring activities completed! CAMBRIDGE (UK), November 10, 2022 – Nanna Therapeutics has attracted a raft of new talent. Meet the newest members of the team: New Head of Biology and Head of Chemistry “I am delighted to welcome Keith Moore as head of biology and Steve Penrose as head of chemistry to Nanna […]
Nanna Therapeutics is a small-molecule focused therapeutics biotech subsidiary of Astellas , a Japanese global pharmaceutical company. Nanna and Mitobridge together comprise of the Mitobridge Division, a US- and UK-based research engine of Astellas reporting in to the Astellas Chief Scientific Officer, together we work as part of the Astellas Primary Focus Mitochondria area of research. Mitobridge is a Boston-based biotech acquired by Astellas in 2018, and Nanna Therapeutics, is a Cambridge, UK-based biotec
Leveraging enabling platforms to develop transformational therapeutics via phenotypic screening and optimization approaches. We focus on early-stage, small-molecule drug discovery research in the area of mitochondrial & rare diseases. Our goal is to discover disease-modifying, transformative new medicines for diseases with significant unmet medical needs.